Evaluating MZE829 for Kidney Disease Related to APOL1 Genotype

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 study aims to assess the safety, tolerability, and impact of MZE829 on albuminuria in adults suffering from proteinuric chronic kidney disease associated with the APOL1 high-risk genotype. The study is open-label, meaning all participants will know they are receiving the treatment. It specifically targets individuals with chronic kidney disease who have persistent albuminuria and possess certain genetic markers. The trial will monitor participants for any adverse effects while measuring changes in kidney function.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2
* Chronic kidney disease with persistent albuminuria

Key Exclusion Criteria:

* Organ or bone marrow transplantation
* History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer
* Conditions that may alter drug absorption, e.g., history of bariatric surgery
* Type I diabetes
* Pregnant or currently nursing

Other inclusion/exclusion criteria defined in protocol apply.

Where it's running

• Research Site
  Decatur, Alabama, United States Recruiting
• Research Site
  Huntsville, Alabama, United States Recruiting
• Research Site
  Montgomery, Alabama, United States Recruiting
• Research Site
  Montgomery, Alabama, United States Recruiting
• Research Site
  Bloomfield, Connecticut, United States Recruiting
• Research Site
  Washington D.C., District of Columbia, United States Recruiting

+29 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Maze Therapeutics
• Email: APOL1info@mazetx.com
• Phone: 650-850-5075

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sparsentan for high-grade proteinuria linked to VEGF inhibitors

  This pilot study tests whether sparsentan can reduce severe proteinuria in adults with cancer who are being treated with VEGF signaling pathway inhibitors.

  Recruiting Phase 1 Brigham and Women's Hospital · Boston, Massachusetts · NCT07224776

• BI 764198 for adults and adolescents with proteinuric kidney diseases

  This trial tests whether the oral medicine BI 764198 can help adults and adolescents who have certain proteinuric kidney diseases, including secondary FSGS, treatment‑resistant minimal change disease, Alport syndrome, or treatment‑resistant membranous nephropathy.

  Recruiting at 115 sites Phase 2 Boehringer Ingelheim · Huntsville, Alabama and 153 other locations · NCT07355296

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.